Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053466 | 0.87 | ALDH1A1 (0.36) | EPAS1ALDH1A1CA2LMNAMAPK1 | |
| SCHEMBL5187074 | 0.75 | KEAP1 (0.34) | — | |
| SCHEMBL447764 | 0.69 | ALDH1A1 (0.37) | EPAS1ALDH1A1CA2LMNAMAPK1 | |
| SCHEMBL16098938 | 0.68 | PSIP1 (0.35) | ALDH1A1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL17289072 | 0.68 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7988077 | 0.67 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4017 | 0.67 | — | — | |
| SCHEMBL10438545 | 0.66 | HSD11B1 (0.43) | ALDH1A1 | |
| SCHEMBL21634571 | 0.64 | — | — | |
| SCHEMBL20954103 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307502-A9 | NICOTINIC RECEPTOR COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-29 | — | — | US | disclosed |
| US-9150581-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140357674-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2014-12-04 | — | — | US | disclosed |
| WO-2013101802-A1 | NICOTINIC RECEPTOR COMPOUNDS | RESEARCH TRIANGLE INSTITUTE (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307502-A9 | NICOTINIC RECEPTOR COMPOUNDS | CHRNB4, CHRNA4, CHRNB2 | EPAS1 3723/4885ALDH1A1 1665/4885CA2 3767/4885 |
| US-20140357674-A1 | NICOTINIC RECEPTOR COMPOUNDS | CHRNB4, CHRNA4, CHRNB2 | EPAS1 3723/4885ALDH1A1 1665/4885CA2 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.